Process · Proof · Quality + Diligence
From Bench Science to Scalable, Audit-Ready Processes.
I help early-stage biotech companies, and the investors and acquirers evaluating them, turn bench-stage science into scalable, well-characterized, audit-ready processes, and give them a straight technical read on a deal.
Who I Help
Building it, funding it, or acquiring it. The same straight technical read.
Early-stage biotech, pre-seed to about Series B, across therapeutics, alt-protein, synbio, devices, and more.
VCs, PE, and family offices backing a biotech company who need a clear read on the science and team.
Strategics and corp-dev teams acquiring a bioprocess asset who want an independent read before they close.
What I Do
Four pillars, from bench to deal.
Process
Development, scale-up, and tech transfer that hold up at GMP and on CDMO handoff.
Proof
Characterization in vitro, ex vivo, and in vivo, plus preclinical testing (ISO 10993, via CRO).
Quality
A quality system right-sized to your regulatory pathway. Audit-ready, without the bureaucracy.
Diligence
A straight technical read on a target's process, data, and team.
Why It Matters
Get the fundamentals right early and everything downstream gets easier: cleaner scale-up, a smoother CDMO handoff, characterization that holds up, and diligence you can walk into with confidence. That is what well-structured, well-proven early-stage work makes possible, and it is what I help you build.
Why Me
12+ years taking recombinant-protein platforms from early-stage R&D to GMP clinical manufacturing.
I have built these processes from the bench up and learned firsthand where they break. I bring those hard-won lessons so you can skip the costly detours and get it right the first time.
- Built an ISO 13485 quality system from scratch.
- Deep process development, scale-up, and tech transfer.
- Characterization and preclinical programs (ISO 10993) with CROs and universities.
- Led technical diligence in a successful acquisition.
- Named inventor on five U.S. patents.
MS Biochemical Engineering, TU Delft.
How I Engage
Flexible engagements, sized to the decision in front of you.
Net-30. Engagement formats and rates on request.
Start a Conversation
Let's build something that lasts.
Tell me about your process, your program, or the asset you're evaluating. I'll tell you straight what the data supports and where the risks are.